A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Osilodrostat (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Pharmacokinetics
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 06 Oct 2019 Planned End Date changed from 28 Sep 2022 to 29 Nov 2022.
- 06 Oct 2019 Planned primary completion date changed from 21 Dec 2021 to 21 Feb 2022.
- 19 Aug 2019 Status changed from not yet recruiting to recruiting.